Generic combo diabetes pill could offer cheaper alternative to Brand-Name drug

NCT ID NCT07691203

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This trial compares a generic extended-release tablet containing three diabetes drugs (empagliflozin, linagliptin, and metformin) to the brand-name Trijardy XR. The study involves 36 healthy adults who take a single dose of each version under fed conditions to see if the generic releases the same amount of medication into the bloodstream. The goal is to prove the generic works just as well, potentially offering a more affordable treatment option for people with type 2 diabetes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
empagliflozin, linagliptin, and metformin hydrochloride extended-release tablet
What this could lead to
If successful, this could provide a more affordable generic version of a three-in-one diabetes medication, helping patients manage blood sugar and reduce cardiovascular risk.
What could go wrong
This is an early-phase bioequivalence study in healthy volunteers, not patients. Even if the generic matches the brand in absorption, it does not guarantee long-term safety or effectiveness in people with diabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cliantha Research Limited

    Ahmedabad, Sarkhej, 382210, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.